Novavax Stock News

A coronavirus subvariant is starting to garner more headlines, leading to greater concern about a surge. The biotech developed one of the three COVID vaccines currently authorized for use in this coun

Investing in growth stocks can be risky, especially for those migrating into new markets or turnaround ventures. Personally, I've experienced losses from such endeavors.

Healthcare continues to lag in the broader market. Year to date, the Standards and Practices (S&P) 500 Health Care index is down 2% versus a 17% gain in the benchmark S&P 500 index.

Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.

It's not the only vaccine producer struggling to get by, but Novavax looked terminal earlier this year by its own admission.

Novavax (NVAX) shares closed lower on Tuesday, despite the company reporting a surprise profit in the second quarter. The biotech company's results got a lift from Covid vaccine sales, but it was forc

Novavax, Inc. (NASDAQ:NVAX ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Erika Schultz - Senior Director, IR John Jacob - President and CEO Filip Dubovsky - CMO Joh

Although the revenue and EPS for Novavax (NVAX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street e

Novavax (NVAX) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $1.24 per share. This compares to loss of $6.53 per share a year ago.

Novavax (NASDAQ: NVAX ) stock is climbing higher on Tuesday after the vaccine company released earnings results for the second quarter of the year. Included in that report is the company's diluted ear

Novavax is working to strengthen its financial position after it raised doubts about its ability to stay in business earlier this year.

Novavax on Tuesday posted an unexpected second-quarter profit on earlier-than-expected revenue from its COVID-19 vaccine, but still trimmed its full-year forecast for sales of the shot.

Novavax stock is on the rise after announcing a cost-cutting plan and bullish sales guidance. Is NVAX stock a buy or a sell today?

GAITHERSBURG, Md. , Aug. 1, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report it

American drug makers can generate gigantic profits, pushing their stock prices to great heights. The pharmaceutical sector is lucrative in general around the globe, while the space is very profitable